Condition

Human Immunodeficiency Virus (HIV) Infection

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 17 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials17
Recruiting3
Common interventions25
Lead sponsors shown12
Advertisement

Clinical trials

17 shown
Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in IndiaNCT07209917 · 2026-02-01
RECRUITING
Strategies to AchieVe Viral Suppression for Youth With HIVNCT06886971 · 2024-11-10
RECRUITING
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)NCT04375800 · 2021-02-03
RECRUITING
Bioequivalence Study of ADC118 Tablets in Healthy Chinese Volunteers Under Fasting ConditionsNCT07753902 · 2026-04-10
COMPLETED
Empowering Knowledge, Self-Testing & Resilience Through Innovative Methods for HIVNCT07039682 · 2025-07-31
NOT_YET_RECRUITING
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ARTNCT06430905 · 2024-07-01
TERMINATED
Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of TuberculosisNCT05452616 · 2022-10-19
COMPLETED
Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)NCT04515641 · 2020-11-05
COMPLETED
Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)NCT04303156 · 2020-06-18
COMPLETED
Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)NCT03667547 · 2018-09-27
COMPLETED
Interventions to Improve HIV Antiretroviral Therapy AdherenceNCT03618511 · 2018-08-06
COMPLETED
Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary InterventionNCT02818283 · 2016-06-01
TERMINATED
Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)NCT02715700 · 2015-09-28
COMPLETED
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected PatientsNCT01422330 · 2011-09-01
COMPLETED
Folinic Acid and Vascular Reactivity in HIVNCT01768182 · 2009-08-01
COMPLETED
Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese VolunteersNCT00821535 · 2009-02-01
COMPLETED
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal FunctionNCT00717067 · 2008-07-01
COMPLETED

Common interventions

DoravirineDRUG2IslatravirDRUG2PlaceboOTHER22 NRTIsDRUG1ACC118-TestDRUG1ART first- Therapeutic use trialOTHER1Digital HIV Education and Self-Screening (EKSTRIM Model)DEVICE1DOR/3TC/TDFDRUG1Enhanced Standard of Care (SOC+)BEHAVIORAL1EtravirineDRUG1Financial IncentiveBEHAVIORAL1Financial Incentive and RemindersBEHAVIORAL1Folinic AcidDIETARY_SUPPLEMENT1HB-502 and HB-501 alternating 2-vector therapy Dose Level 1BIOLOGICAL1HB-502 and HB-501 alternating 2-vector therapy Dose Level 2BIOLOGICAL1InformationBEHAVIORAL1Information and Stigma-relievingBEHAVIORAL1MaravirocDRUG1maraviroc (Selzentry, Celsentri)DRUG1MethadoneDRUG1RaltegravirDRUG1ReferenceDRUG1RemindersBEHAVIORAL1RitonavirDRUG1SAKHI HPV InterventionBEHAVIORAL1

Trial status mix

COMPLETED11
RECRUITING3
TERMINATED2
NOT_YET_RECRUITING1

Phase mix

NA7
PHASE16
PHASE43
PHASE21
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.